The estimated Net Worth of Joel K Caldwell is at least $45.9 mil dollars as of 7 August 2020. Mr. Caldwell owns over 450,000 units of LadRx Corp stock worth over $45,900 and over the last 7 years he sold CYTR stock worth over $0. In addition, he makes $0 as Director at LadRx Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Caldwell CYTR stock SEC Form 4 insiders trading
Joel has made over 1 trades of the LadRx Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 450,000 units of CYTR stock worth $117,000 on 7 August 2020.
The largest trade he's ever made was exercising 450,000 units of LadRx Corp stock on 7 August 2020 worth over $117,000. On average, Joel trades about 112,500 units every 0 days since 2017. As of 7 August 2020 he still owns at least 510,000 units of LadRx Corp stock.
You can see the complete history of Mr. Caldwell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Joel Caldwell biography
Joel Caldwell has been appointed as Director of the Company., effective July 12, 2017. e brings more than 30 years of experience in tax matters, finance and internal auditing. Mr. Caldwell retired from Southern California Edison, one of the nation’s largest public utilities, where he had been employed for 28 years in various executive-level accounting and finance positions covering Internal Audits, Executive Compensation, Long Term Finance, Employee Benefits and, most recently prior to his retirement, Sarbanes-Oxley Internal Controls Compliance. He also worked in public accounting at the firm of Arthur Andersen & Co. Mr. Caldwell volunteers his business skills, serving as a financial advisor on the board of trustees of a charitable organization, and continues his involvement with track and field sports by volunteering as a meet official at Pacific Palisades Charter High School. He holds B.S. and M.B.A. degrees from the University of California, Berkeley. Mr. Caldwell has been a Certified Public Accountant in California since 1982 and a Certified Internal Auditor since 1986. He is a member of both the American Institute of Certified Public Accountants and the California Society of Certified Public Accountants. His diverse background in accounting, auditing and finance will provide the board with a balanced perspective to enhance its stewardship of the Company.
How old is Joel Caldwell?
Joel Caldwell is 65, he's been the Director of LadRx Corp since 2017. There are 4 older and 4 younger executives at LadRx Corp. The oldest executive at LadRx Corp is Louis Ignarro, 79, who is the Independent Director.
What's Joel Caldwell's mailing address?
Joel's mailing address filed with the SEC is 11726 SAN VICENTE BLVD., SUITE 650, , LOS ANGELES,, CA, 90049.
Insiders trading at LadRx Corp
Over the last 21 years, insiders at LadRx Corp have traded over $0 worth of LadRx Corp stock and bought 3,710,406 units worth $8,711,088 . The most active insiders traders include Steven A Kriegsman, Scott Bradford Patterson, eMax Link. On average, LadRx Corp executives and independent directors trade stock every 177 days with the average trade being worth of $22,531. The most recent stock trade was executed by Earl W Brien on 14 August 2020, trading 150,000 units of CYTR stock currently worth $39,000.
What does LadRx Corp's logo look like?
Complete history of Mr. Caldwell stock trades at LadRx Corp
LadRx Corp executives and stock owners
LadRx Corp executives and other stock owners filed with the SEC include:
-
Steven Kriegsman,
Chairman of the Board, Chief Executive Officer -
Steven A. Kriegsman,
Chief Exec. Officer -
John Caloz,
Chief Financial Officer, Chief Accounting Officer, IR Contact Officer -
John Y. Caloz,
CFO, Treasurer & Sr. VP -
Louis Ignarro,
Independent Director -
Joel Caldwell,
Director -
Earl Brien,
Director -
Dr. Felix Kratz Ph.D.,
Sr. VP, Drug Devel. -
Cristina Newman,
Corp. Sec. -
Terri Stevens,
Chief Bus. Officer -
Molly Painter,
Pres of USA and Head of Launch & Commercial Operations -
Molly Carey Poarch,
Global & U.S. Head of Corp. Communications -
Jennifer K. Simpson,
Director -
Anita J Chawla,
Director -
Daniel J Levitt,
Chief Medical Officer -
Joseph Rubinfeld,
Director -
Olivia C Ware,
Chief Commercial Officer -
Douglas Scott Wieland,
Sr. VP - Drug Development -
Felix Kratz,
Vice President Drug Discovery -
Herbert H Jr Mcdade,
-
Alexander L Cappello,
Director -
Raymond C Jr Carnahan,
-
Ben Levin,
Gen.Cnsl/VP Legal Affairs/Secy -
Eric Jay Selter,
Director -
Cheryl Cohen,
Director -
Scott Bradford Patterson,
10% owner -
Marvin R Selter,
Director -
Richard J Wennekamp,
Director -
Max Link,
Director -
David Scott Geyer,
Sr. V.P. of Manufacturing -
Mitchell K Fogelman,
Chief Financial Officer -
Jack R Barber,
Sr VP - Drug Development -
Shi Chung Ng,
Sr. VP Research & Development -
Matt Natalizio,
Chief Financial Officer -
Mark Tepper,
Vice President -
Stephen Snowdy,
Chief Executive Officer